An experimental drug for acute myelogenous leukemia might potentially help many more patients than previously thought by controlling epigenetic processes, according to a recent MSK study.
Physician-scientist Omar Abdel-Wahab explains epigenetics, a growing field based on the study of genetic changes that are not part of the DNA code, and how it relates to cancer.
Memorial Sloan Kettering physician-scientists have prevented a dangerous complication of stem cell transplantation using immune cells donated from a third party.
Pediatric oncologist Paul Meyers gives us a snapshot of where treatment for childhood cancers has been – and the promising directions it’s taking in the future.
Memorial Sloan Kettering specialists provide state-of-the-art care for a range of pediatric blood disorders.
On the occasion of Childhood Cancer Awareness Month, pediatric oncologist Paul A. Meyers talks about the evolution of pediatric cancer research and treatment at Memorial Sloan Kettering.
Researchers have found the first evidence that susceptibility to developing acute lymphoblastic leukemia during childhood may be heritable.
In this “Ask the Expert” feature, pediatric hematologist Andromachi Scaradavou discusses options for expectant parents who are considering banking a newborn’s cord blood.
Scott Armstrong specializes in the treatment of leukemia in children. His research focuses on the disease in children and adults.
Researchers have identified a set of genetic abnormalities that can enhance prognostic accuracy and aid treatment selection for people with acute myelogenous leukemia (AML).
Geneticist Kenneth Offit and colleagues discovered a genetic link specific to risk of childhood leukemia that could potentially be used to prevent the disease in leukemia-prone families.